Even if all series B, C and D preferred shares wer

Even if all series B, C and D preferred shares were converted to common shares it would fall far short of 200 million shares.

The maximum number of authorized shares of series B is 400,000 with a conversion rate to common shares of 1 to 10. This would equal 4,000,000 shares.

The maximum number of authorized shares of series C is 8,203 with a conversion rate to common shares of 1 to 2,000. This would equal 16,406,000 million shares.

The maximum number of authorized shares of series D is 11,737 with a conversion rate to common shares of 1 to 2,000. This would equal 23,474,000 million shares.

Even if all preferred shares had been sold by Cytodyn and converted to common shares the maximum number of common shares would be 43,880,000 shares.

The amount of preferred shares already sold is much less than the maximum shares authorized. Any increase in the maximum number of preferred shares is subject to a vote from shareholders of common stock. Preferred shares are not eligible to vote on any matter.

Reference for maximum number of shares and conversion rates -
https://www.sec.gov/Archives/edgar/data/11756...xex3d1.htm